Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat
Christen Lykkegaard Andersen(Copenhagen University Hospital), Hans Carl Hasselbalch(Zealand University Hospital), Kirsten Grønbæk(University of Copenhagen), Savio Fernandes(Russells Hall Hospital), Mads Emil Bjørn(Roskilde Sygehus), Tobias Wirenfeldt Klausen(Copenhagen University Hospital), Eva Löfvenberg(Karolinska University Hospital), Torben Mourits‐Andersen(Hospital South West Jutland), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Jan Samuelsson(Karolinska University Hospital), Hanne Vestergaard(Odense University Hospital), Björn Andréasson(NU Hospital Group), Vibe Skov(Odense University Hospital), Mary Frances McMullin(Queen's University Belfast), D. Bareford(Birmingham City Hospital), Olle Linder(Örebro University Hospital), Sonja Zweegman(Vrije Universiteit Amsterdam), Erik Ahlstrand(Örebro University), Torben A. Kruse(Odense University Hospital), Morten Krogh Jensen(Herlev Hospital), Ole Weis Bjerrum(Rigshospitalet), Mads Thomassen(Odense University Hospital), Steven Knapper(Cardiff University), Herdis Larsen(Regionshospitalet Viborg), Elisabeth Ejerblad(Uppsala University)
Cited by 13
Related Papers
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism
|New England Journal of Medicine|1997|611